NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LXRX stock has decreased by 14.5% and is now trading at $1.94. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) issued its quarterly earnings data on Monday, April, 27th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.06. The biopharmaceutical company earned $8 million during the quarter, compared to analyst estimates of $7.18 million. Lexicon Pharmaceuticals had a return on equity of 125.61% and a net margin of 26.59%. View Lexicon Pharmaceuticals' earnings history.

6 analysts have issued twelve-month price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $2.10 to $9.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $4.53 in the next year. This suggests a possible upside of 133.2% from the stock's current price. View analysts' price targets for Lexicon Pharmaceuticals.

Headlines about LXRX stock have trended neutral recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 10,920,000 shares, an increase of 8.5% from the June 15th total of 10,060,000 shares. Based on an average daily trading volume, of 929,400 shares, the days-to-cover ratio is currently 11.7 days. Approximately 10.6% of the shares of the company are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Geron (GERN), Orexigen Therapeutics (OREX), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Micron Technology (MU).

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.08%), Diversified Trust Co (0.02%) and Investors Financial Group LLC (0.01%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker. View institutional ownership trends for Lexicon Pharmaceuticals.

LXRX stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Diversified Trust Co, and Investors Financial Group LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker. View insider buying and selling activity for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $1.94.

Lexicon Pharmaceuticals has a market capitalization of $207.52 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.